Pfizer: Vaccine is 100 percent effective in teenagers

Pfizer and BioNTech’s COVID-19 vaccine was 100 percent effective at protecting teenagers between the ages of 12 and 15, the companies said Monday.

The results of a long-term study with 2,228 adolescents, measured from seven days to more than four months after the second dose, form the basis for a planned supplementary application to the Food and Drug Administration (FDA) to expand the approval of the vaccine for use in humans in that age group, the companies said.

The data was collected from November 2020 to September 2021, when the Delta variant began to infect large swaths of the US population.

The vaccine is currently available to people ages 12-15 in the event of an emergency that was granted in May.

“As the global health community works to increase the number of people vaccinated around the world, this additional data will give further confidence in the safety and efficacy profile of our vaccine in adolescents,” said Albert Bourla, CEO of Pfizer.

Effectiveness was consistently high across gender, race and ethnicity, obesity, and comorbidity, the companies said.

In addition, there were no serious safety concerns for at least six months of follow-up after the second dose of vaccine.

There were 30 symptomatic infections in the study, all in the placebo arm.

“This is the first and only longer-term data to demonstrate the safety and effectiveness of a COVID-19 vaccine in people ages 12-15,” said Ugur Sahin, CEO and co-founder of BioNTech. “The growing amount of data that we have compiled so far from clinical studies and real-world surveillance strengthens the evidence base for the strong efficacy and favorable safety profile of our COVID-19 vaccine in adolescents and adults.

Leave a Comment